Drug Information

Drug General Information
Drug ID
D0GP9Q
Former ID
DIB011665
Drug Name
TG100801
Drug Type
Small molecular drug
Indication Macular degeneration [ICD9: 362.5; ICD10:H35.3] Phase 2 [522077]
Company
TargeGen
Structure
Download
2D MOL

3D MOL
Formula
C33H30ClN5O3
Canonical SMILES
CC1=C2C(=CC(=C1)C3=C(C=CC(=C3)OC(=O)C4=CC=CC=C4)Cl)N=NC<br />(=N2)NC5=CC=C(C=C5)OCCN6CCCC6
InChI
1S/C33H30ClN5O3/c1-22-19-24(28-21-27(13-14-29(28)34)42-32(40)23-7-3-2-4-8-23)20-30-31(22)36-33(38-37-30)35-25-9-11-26(12-10-25)41-18-17-39-15-5-6-16-39/h2-4,7-14,19-21H,5-6,15-18H2,1H3,(H,35,36,38)
InChIKey
JMGXJHWTVBGOKG-UHFFFAOYSA-N
PubChem Compound ID
11973736
PubChem Substance ID
17425569, 24489274, 36469958, 57378097, 74741593, 103578818, 126636420, 135262188, 141861964, 152258110, 152344165, 160646949, 163409511, 163847623, 164039215, 172919684, 180405978, 185965452, 198962314, 237299816, 249159939, 252216455, 252478718
Target and Pathway
Target(s) VEGF ligand Target Info Inhibitor [529366]
References
Ref 522077ClinicalTrials.gov (NCT00509548) Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD. U.S. National Institutes of Health.
Ref 529366Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.